Go Pro
NASDAQ:ONC

BeOne Medicines Q1 2025 Earnings Report

BeOne Medicines logo
$325.90 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$325.83 -0.06 (-0.02%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$1.22
Consensus EPS
-$0.71
Beat/Miss
Beat by +$1.93
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.12 billion
Expected Revenue
$1.12 billion
Beat/Miss
Missed by -$7.30 million
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BeOne Medicines' Q2 2026 earnings is scheduled for Wednesday, August 5, 2026, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

BeOne Medicines Earnings Headlines

Morgan Stanley Reaffirms Their Buy Rating on BeOne Medicines (ONC)
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile